FindTrial
Sign In

Pemetrexed + carboplatin

DRUG5 trials

Sponsors

AstraZeneca, Betta Pharmaceuticals Co., Ltd.

Conditions

Adjuvant Drug TherapyEGFRNSCLCNon Small Cell Lung Cancer NSCLCNon Small Cell Lung Carcinoma NSCLCNon-Small-Cell Lung Carcinoma NSCLC

Phase 2

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
RecruitingNCT07181499
Betta Pharmaceuticals Co., Ltd.Adjuvant Drug Therapy, EGFR, NSCLC
Start: 2025-09-30End: 2028-12-31Target: 28Updated: 2025-09-30

Phase 3

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
Active, not recruitingNCT02453282
AstraZenecaNon-Small-Cell Lung Carcinoma NSCLC
Start: 2015-07-21End: 2026-12-31Updated: 2026-03-02
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
Active, not recruitingNCT02542293
AstraZenecaNon Small Cell Lung Carcinoma NSCLC
Start: 2015-11-03End: 2026-12-31Updated: 2026-02-12
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
Active, not recruitingNCT03003962
AstraZenecaNon Small Cell Lung Carcinoma NSCLC
Start: 2017-01-02End: 2026-06-30Updated: 2026-03-11
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
Active, not recruitingNCT03164616
AstraZenecaNon Small Cell Lung Cancer NSCLC
Start: 2017-06-01End: 2027-11-15Updated: 2026-03-13

Related Papers

Abstract 4123: Dissecting the baseline tumor microenvironment in mNSCLC by transcriptional profiling identifies tumor microenvironmental conditions predictive for immunotherapy response
Cancer Research2026-04-03
Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC
npj Precision Oncology2025-09-18
Abstract 5781: Comparing prognostic association of manual vs. artificial intelligence derived quantifications from baseline computed tomography scans in MYSTIC, a global phase 3 trial for treatment of metastatic non-small cell lung cancer
Cancer Research2025-04-21
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.
2024-11-071 citations
TRITON: Phase 3b study of tremelimumab (T) + durvalumab (D) vs pembrolizumab (P), in combination with chemotherapy (CT), in non-squamous (NSQ) metastatic NSCLC (mNSCLC) with <i>STK11</i>and/or <i>KEAP1</i> and/or <i>KRAS</i> mutations.
Journal of Clinical Oncology2024-06-017 citations
Abstract 2492: Enhanced patient selection for anti-PD-L1 treatment in metastatic NSCLC with quantitative continuous scoring of PD-L1
Cancer Research2024-03-221 citations
Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer
JCO Precision Oncology2024-03-0112 citations
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.
2024-02-1310 citations
605 Computational pathology-based digital twins enable the discovery of predictive biomarkers for precision immuno-oncology
Regular and Young Investigator Award Abstracts2023-10-31
Abstract CT080: Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) in 1L metastatic NSCLC: Outcomes by blood tumor mutational burden (bTMB) in POSEIDON
Cancer Research2023-04-142 citations
Assoziation von KRAS/STK11/KEAP1 Mutationen und Outcome in der POSEIDON Studie: Durvalumab+/− Tremelimumab+Chemotherapie beim metastasierten NSCLC (mNSCLC)
Pneumologie2023-03-01
NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer.
2023-02-017 citations
583 Quantitative computational assessment of PD-L1 enables robust patient selection for biomarker-informed anti-PD-L1 treatment of NSCLC patients
Regular and Young Investigator Award Abstracts2022-11-012 citations
591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data
Regular and Young Investigator Award Abstracts2022-11-01
581 Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC
Regular and Young Investigator Award Abstracts2022-11-01
Durvalumab (D) +/- tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON.
Journal of Clinical Oncology2022-06-01
Durvalumab +/− Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase III POSEIDON Study
Pneumologie2022-05-011 citations
Abstract 489: Association between immune-mediated adverse events and survival in patients with metastatic non-small cell lung cancer treated with durvalumab and tremelimumab
Cancer Research2021-07-01
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
2020-06-1544 citations
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
JAMA Oncology2020-04-09615 citations

6 more papers not shown